title: MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients.
abstract: We investigated the survival after laser-induced interstitial thermotherapy in 16 patients suffering from recurrent glioblastoma multiforme. The concept underlying the intervention is the cytoreduction of the tumor tissue by local thermocoagulation. All patients received standard chemotherapy (temozolomide). The median overall survival time after the first relapse was 9.4 months, corresponding to a median overall survival time after laser irradiation of 6.9 months. During the study, however, the median survival after laser coagulation increased to 11.2 months. This survival time is substantially longer than those reported for the natural history (<5 months) or after chemotherapy (temozolomide: 5.4-7.1 months). We conclude that cytoreduction by laser irradiation might be a promising option for patients suffering from recurrent glioblastoma multiforme. In addition, the data indicate the presence of a substantial learning curve. Future work should optimize the therapeutic regimen and evaluate this treatment approach in controlled clinical trials.
authors.affiliation: Center for Medical Research, Klinikum Krefeld, University of Düsseldorf Medical School at Krefeld, Germany. schwarzmaier@klinikum-krefeld.de
authors.forename: Hans-Joachim
authors.initials: HJ
authors.lastname: Schwarzmaier
authors.forename: Frank
authors.initials: F
authors.lastname: Eickmeyer
authors.forename: Wernholt
authors.initials: W
authors.lastname: von Tempelhoff
authors.forename: Volkhard Ulrich
authors.initials: VU
authors.lastname: Fiedler
authors.forename: Hendrik
authors.initials: H
authors.lastname: Niehoff
authors.forename: Slif Dagobert
authors.initials: SD
authors.lastname: Ulrich
authors.forename: Qin
authors.initials: Q
authors.lastname: Yang
authors.forename: Frank
authors.initials: F
authors.lastname: Ulrich
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000188:drug therapy / Q000601:surgery*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005240:Feasibility Studies; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D017075:Laser Coagulation; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000601:surgery*; D000077204:Temozolomide; D013696:Temperature
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide